POSTER SESSION IV Tuesday, March 1, 2005   —  1:00 - 4:30 PM Convention Center Exhibit Hall B GASTROINTESTINAL PATHOLOGY 55 Management of Superficial Barrett's Epithelium (BE) Related Neoplasms by Endoscopic Mucosal Resection (EMR): Evaluation of 27 Cases (511) M Mino, LR Zukerberg, J Misdraji, GY Lauwers - Massachusetts General Hospital, Boston, MA 56 Significance of the Depth of Tumor Invasion in Early (T1) Esophageal Adenocarcinoma (501) L Liu, W Hofstetter, A Rashid, S Swisher, A Correa, S Hamilton, T-T Wu - The University of Texas M. D. Anderson Cancer Center, Houston, TX 57 Patterns of Expression of PIGR in Pre-Neoplastic Mucosa and Adenocarcinomas of the Upper Gastrointestinal Tract (473) A Gologan, M Acquafondata, R Dhir, A Sepulveda - University of Pittsburgh Medical Center, Pittsburgh, PA 58 Chromosome and Gene Copy Alterations in Barrett's Esophagus (BE)-Associated Superficial Esophageal Adenocarcinoma: Fluorescence In Situ Hybridization (FISH) Study (465) EA El Gabry, JR Goldblum, TW Rice, RR Tubbs, M Skacel - Cleveland Clinic Foundation, Cleveland, OH 59 CDX-2 Expression in Upper Gastrointestinal Tract Adenocarcinomas (527) TC Pereira, YL Liu, JF Silverman - Allegheny General Hospital, Pittsburgh, PA 60 Concordant Loss of MTAP and p16/CDKN2A Expression in Barrett Esophagus and Adenocarcinoma: Evidence of Homozygous Deletion in Non-Invasive Precursor Lesions (528) EL Powell, E Montgomery, L Leoni, A Maitra - Johns Hopkins University, Baltimore, MD; San Diego, CA 61 PML Protein Expression in Esophageal Carcinoma (491) P Khanna, RA Delellis, YE Chin, LJ Wang - Rhode Island Hospital and Brown University School of Medicine, Providence 62 EphA2 Expression in Esophageal Cancers (492) P Khanna, RA Delellis, YE Chan, LJ Wang - Rhode Island Hospital and Brown University School of Medicine, Providence, RI 63 Loss of HepPar-1 Antibody Reactivity as a Marker of Dyspastic Barrett's Mucosa and Esophageal Adenocarcinoma (529) N Rekhtman, B Bhattacharya, E Montgomery - The Johns Hopkins Hospital, Baltimore, MD 64 MSH-2, MCM7 and KI-67 Are Useful Markers in the Diagnosis of Barrett's Associated Neoplasia (531) J Richmond, L de Quartel, L Simmons-Arnold, B Beatty, H Blaszyk, A Elhosseiny - University of Vermont College of Medicine, Burlington, VT; Fletcher Allen Health Care, Burlington, VT 65 MUC1, 2, 5AC, and 6 Expression Pattern in Barrett's Metaplasia, Barrett's Related Dysplasia and Adenocarcinoma (538) P Sharma, Z Gatalica, Z Nawaz, S Prasad - Creighton University Medical Center, Omaha, NE 66 Loss of Cables, a Cyclin-Dependent Kinase (CDK) Interacting Protein, Is Frequent in Intestinal Type Gastric Dysplasia and Early Gastric Cancer (512) M Mino, SD Kirley, GY Lauwers, LR Zukerberg - Massachusetts General Hospital, Boston, MA 67 CDX2 Expression in 259 Gastric Carcinomas-Its Relationship with Mucin Phenotypes and Clinicopathological Characteristics (523) DY Park, DH Shin, JY Kim, KU Choi, HW Kim, CH Lee, GY Huh, MY Sol - College of Medicine Pusan National University, Busan, Korea 68 Microsatellite Instability Does Not Correlate with Clinicopathologic Features in Gastric Cancers (440) YK Bae, JH Choi, MJ Kim, SW Kim, SK Song - Yeungnam University Medical Center, Daegu, Korea 69 Cell Cycle Regulators and Apoptosis-Related Proteins in Epstein-Barr Virus Associated Gastric Carcinomas (448) MS Chang, HS Lee, EJ Chung, CW Kim, BL Lee, WH Kim - Seoul National University Boramae Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea 70 Evaluation of Activated Nuclear Factor KB (NF-kb) in Gastric Adenocarcinoma (449) Y Chen, XD Tan, MS Rao - Feinberg School of Medicine, Northwestern University, Chicago, IL; Children's Memorial Hospital, Northwestern University, Chicago, IL 71 Claudin 1 and Claudin 4 Expression in Distal Gastric Adenocarcinomas (469) M Gavilanez, T Konkin, E Newton, B Bhattacharya, B Wilson, SF Moss, MB Resnick - Rhode Island Hospital, Providence, RI 72 Overexpression of Phosphorylated Histone H3 Is an Independent Prognostic Indicator in Gastric Cancer Patients (548) H Takahashi, R Hori, K Nomoto, Y Takano - Toyama Medical and Pharmaceutical University School of Medicine, Toyama, Japan 73 Expression of IGFBP2 in Carcinoid Tumors and Pancreatic Endocrine Tumors (556) H Wang, H Wang, JC Yao, TT Wu, W Zhang, GN Fuller, SR Hamilton, A Rashid - The University of Texas M. D. Anderson Cancer Cencer 74 Gastric Carcinoid Tumors: The Pathological Spectrum of an Immune Conundrum (549) LH Tang, D Coit, MF Brennan, DS Klimstra - Memorial Sloan-Keterring Cancer Center, New York, NY 75 Mucosal Epithelioid Nerve Sheath Tumors; a Clinicopathologic Study of a Novel Mucosal-Based Neoplasm (499) MR Lewin, HP Dilworth, AK Abu Alfa, JI Epstein, E Montgomery - Johns Hopkins Hospital, Baltimore, MD; Dianon Systems/ Laboratory Corporation of America 76 NFI Associated Gastrointestinal Stromal Tumors (GIST) Have Unique Clinical and Phenotypic and Genotypic Characteristics (495) LG Kindblom, J Andersson, H Sihto, H Joensuu, JM Meis-Kindblom - Sahlgrenska University Hospital, Gothenburg, Sweden; University of Helsinki, Helsinki, Finland 77 Characteristic and Unusual Pathological Features of a New Familial GIST Kindred (517) C O'Riain, C Corless, M Heinrich, D Keegan, M Vioreanu, D Maguire, K Sheahan - St. Vincent's University Hospital, Dublin, Ireland; Oregon Health and Sciences University, Portland, OR 78 Pleomorphic Gastrointestinal Stromal Tumors: Diagnostic and Therapeutic Implications (554) P Verma, CL Corless, F Medeiros, RB West, MC Heinrich, CD Fletcher, BP Rubin - University of Washington Medical Center, Seattle, WA; Oregon Health and Science University, Portland, OR; Brigham and Women's Hospital, Boston, MA; Stanford University Medical Center, Stanford, CA 79 Immunohistochemical Expression of Fatty Acyd Synthase (FAS) in GIST (533) S Rossi, S Chinellato, N Bhattacharya, AP Dei Tos, M Loda - Hospital of Treviso, Treviso, Italy; Dana Farber Cancer Institute, Boston, MA